AUG 2 1

TRANSMITTAL FORM (to be used for all correspondence after initial of the submission)	Application Number Filing Date First Named Inventor Art Unit Examiner Name	Patent and Trademar		031 RCE ///
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocati Change of Correspondence Terminal Disclaimer Request for Refund CD, Number of CD(s) 1 Landscape Table on Correspondence Remarks Other Enclosures (con't):Substitute paper copy of the Sequence Paper Correspondence Return-receipt postcard	AddressCr	After Allowance Communication to Tappeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): Dry of Notice to Comply (2 pages) Dry of Raw Sequence Listing irror Report (3 pages)	
Firm Name HOXIE &TSO LLP Signature Printed name Arthur Yang Date August 18, 2006 I hereby certify that this correspondence is b sufficient postage as first class mail in an enthe date shown below:	ERTIFICATE OF TRANSMISS eing facsimile transmitted to the USP velope addressed to: Commissioner f	Reg. No. 45,72 SION/MAILING TO or deposited wi	th the United States Postal Service wit	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



<u>S/N 10/550,866</u> <u>PATENT</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Drivas et al.)	Examiner: TBD
)	
Serial No.:	10/550,866)	Group Art Unit: TBD
)	
I.A. Filing Date: 3/24/2004)	Confirmation No.: 1389
_)	
Title:	Methods and Compositions for	.)	Attorney Docket: MP-02-US
	Treating and Preventing Eotaxin)	
	Mediated Inflammatory Conditions)	

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Mail Stop Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

In response to the Notice to Comply with Requirements for Patent Applications

Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated June 21, 2006

("Notice to Comply") with regard to US Patent Application No. 10/550,866, Applicants hereby submit:

- 1. Copy of Notice to Comply;
- 2. Copy of Raw Sequence Listing Error Report;
- A substitute computer readable form copy of the "Sequence Listing" (1 compact disk);
 - 4. A substitute paper copy of the Sequence Listing (49 pages).

In accordance with the requirements under 37 CFR § 1.821(f), I hereby state:

- 1. the substitute copy of the computer readable form submitted hereunder is the same as the substitute paper copy of the Sequence Listing; and
- 2. the substitute copy of the computer readable form and paper copy of the Sequence Listing do not include any new matter.

It is believed that no fee is required. If a fee is required, please charge the same to Deposit Account 50-3464.

Respectfully submitted, Hoxie & Tso LLP

Date: August 18, 2006

Arthur Yang/

Reg. No. 45,721 Hoxie & Tso LLP 374 Millburn Avenue

Suite 300E

Millburn, NJ 07041



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginis 22313-1450 www.upio.gov

OC00000019350248

U.S. APPLICATION NUMBER NO. FIRST NAMED APPLICANT ATTY. DOCKET NO. 10/550,866 Dimitrios T Drivas MP-02 OIP INTERNATIONAL APPLICATION NO. IPE PCT/US04/08901 50446 I.A. FILING DATE PRIORITY DATE **HOXIE & TSO LLP** 03/24/2004 03/24/2003 374 MILLBURN AVENUE SUITE 300 E MILLBURN, NJ 07041 **CONFIRMATION NO. 1389 371 FORMALITIES LETTER**

Date Mailed: 06/21/2006

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.



MAMIE P PERSON

RECEIVED
JUN 26 2006
HOXIE & TSO LLP

Telephone: (703) 308-9140 EXT 227

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/550,866	PCT/US04/08901	MP-02

FORM PCT/DO/EO/922 (371 Formalities Notice)